[1]Ko JJ，Tudor R，Li H，et al.Reasons for lack of referral to medical oncology for systemic therapy in stage Ⅳ non-small-cell lung cancer：Comparison of 2003-2006 with 2010-2011［J］.Current Oncology，2017，24(6)：486-493.
[2]Lin GN，Peng JW，Liu PP，et al.Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment［J］.Asia-pacific Journal of Clinical Oncology，2017，13(5)：2696-2703.
[3]Soria JC，Tan DS，Chiari R，et al.First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer（ASCEND-4)：A randomised，open-label，phase 3 study［J］.Lancet，2017，389(10072)：917-929.
[4]Peng Dongxu，Fang Xiaojuan，Du Junxiang，et al.Effect of pemetrexed and cisplatin chemotherapy on serum tumor markers in patients with advanced non-small cell lung cancer［J］.Clinical Pulmonary Journal，2016，21(7)：1306-1309.［彭东旭，方晓娟，杜均详，等.培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响［J］.临床肺科杂志，2016，21(7)：1306-1309.］
[5]Kong Haixia，Li Hongjuan，Xu Jingyue，et al.Changes in serum MMP-9，HE4，CYFRA21-1，CEA，NSE and its clinical significance in patients with lung cancer and its clinical significance［J］.Shandong Medicine，2017，57(32)：73-75.［孔海霞，李洪娟，徐婧玥，等.肺癌患者血清MMP-9、HE4、CYFRA21-1、CEA、NSE水平变化及其临床意义［J］.山东医药，2017，57(32)：73-75.］
[6]Chun SG，Chen H，Choy H，et al.Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer：A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial［J］.J Clin Oncol，2017，35(1)：56-62.
[7]Bing T，Yan X，Jing Z，et al.Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy［J］.Oncotarget，2017，8(49)：86615-86624.
[8]Yu Yabo，Cong Zhanjie.ECOG score，CYFRA21-1，NSE and surgical prognosis in elderly non-small cell lung cancer［J］.Clinical and Experimental Pathology，2017，33(7)：806-809.［于亚波，丛占杰.老年非小细胞肺癌ECOG评分、CYFRA21-1、NSE与外科手术预后关系［J］.临床与实验病理学杂志，2017，33(7)：806-809.］
[9]Tian Wei，Dou Yaiwei，Dai Yun，et al.The clinical efficacy of different chemotherapy regimens in the treatment of advanced non-small cell lung cancer and the correlation of tumor markers and efficacy［J］.Hebei Medicine，2016，22(8)：1305-1307.［田伟，豆亚伟，戴云，等.不同化疗方案治疗晚期非小细胞肺癌的临床疗效及肿瘤标志物与疗效的相关性研究［J］.河北医学，2016，22(8)：1305-1307.］
[10]Gong Yufang，Liu Feng，Yang Zhiyin，et al.Changes of serum CA125，CEA and CYFRA21-1 in patients with non-small cell lung cancer before and after neoadjuvant chemotherapy and prognosis analysis［J］.Chinese Medicine Guide，2017，4(11)：91-94.［龚玉芳，刘峰，杨志胤，等.新辅助化疗前后非小细胞肺癌患者血清CA125、CEA及CYFRA21-1的变化及预后分析［J］.中国医药导报，2017，4(11)：91-94.］
[11]Ji Yuqiao，Sun Mingzhong，Zhu Hui，et al.The diagnostic value of serum miRNA-21 and tumor markers CEA，CYFRA21-1，NSE for early non small cell lung cancer［J］.Chinese Experimental Diagnostics，2017，21(4)：576-581.［季禹乔，孙明忠，朱晖，等.血清miRNA-21与肿瘤标志物CEA、CYFRA21-1、NSE对早期非小细胞肺癌的诊断价值［J］.中国实验诊断学，2017，21(4)：576-581.］
[12]Xie Baoquan，Zhang Zhiyan，Wang Yuan，et al.The value of serum CEA，CYFRA21-1 and SCCA detection in predicting the prognosis of patients with lung cancer［J］.Shandong Medicine，2017，57(5)：54-56.［解宝泉，张志艳，王袁，等.血清CEA、CYFRA21-1及SCCA检测对肺癌患者预后的评估价值［J］.山东医药，2017，57(5)：54-56.］
[13]Wang Qiang，Chen Chuanyan，Wang Dongsheng，et al.The diagnostic value of serum HE4，CEA，NSE，and Cyfra21-1 in the diagnosis of lung cancer［J］.Chongqing Medicine，2017，46(26)：3721-3722.［王强，陈传艳，王东生，等.血清HE4、CEA、NSE和Cyfra21-1联合检测在肺癌中的诊断价值［J］.重庆医学，2017，46(26)：3721-3722.］
[14]Xu Lifang，Hu Ke.The clinical significance of combined detection of serum CEA，SCCA，CYFRA21-1，NSE and plasma D-D for the diagnosis of lung cancer［J］.Clinical Pulmonary Journal，2017，22(2)：233-237.［许利芳，胡克.血清CEA、SCCA、CYFRA21-1、NSE与血浆D-D联合检测对肺癌诊断的临床意义［J］.临床肺科杂志，2017，22(2)：233-237.］
[15]Zuo Jianghua，Li Zongliang，Ren Hongtao.The value of combined detection of serum CEA，CA125，and CA199 in the diagnosis of lung cancer［J］.Labeling Immunoassay and Clinical，2016，23(6)：668-671.［左江华，李宗良，任宏涛.血清CEA、CA125、CA199联合检测在肺癌诊断中的应用价值［J］.标记免疫分析与临床，2016，23(6)：668-671.］
[16]Du Junhua，Qiao Hongyuan，Yin Yifa.The effect of serum CEA，CA125，and Cyfra21-1 levels on the prognosis of patients with advanced non-small cell lung cancer［J］.Tumor Prevention and Control，2016，43(2)：137-140.［杜军华，乔洪源，尹宜发.血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响［J］.肿瘤防治研究，2016，43(2)：137-140.］
[17]Wang Qianrong，Chen Yan，Si Xiaoming，et al.The relationship between serum CEA，CA125 and the mutation rate of EGFR in NSCLC patients［J］.Modern Oncology，2014，22(09)：2101-2105.［王倩荣，陈衍，斯晓明，等.血清肿瘤标志物CEA、CA125与肺癌EGFR突变率的相关性［J］.现代肿瘤医学，2014，22(09)：2101-2105.］